Ribavirin therapeutic drug monitoring: why, when and how?

Recent studies suggest the potential interest of ribavirin therapeutic drug monitoring to improve sustain virological response rate in hepatitis C virus‐infected patients. The present review details the pharmacokinetic properties of ribavirin, suggesting that it may be a good candidate for therapeutic drug monitoring, the different possible strategies and the analytical methods that could be employed.

[1]  P. Marquet,et al.  Feasibility of Ribavirin Therapeutic Drug Monitoring in Hepatitis C , 2009, Therapeutic drug monitoring.

[2]  V. Soriano,et al.  Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. , 2008, The Journal of antimicrobial chemotherapy.

[3]  C. Pasquier,et al.  Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV , 2008, Journal of medical virology.

[4]  T. Arakawa,et al.  Correlation of serum ribavirin concentration with pretreatment renal function estimates in patients with chronic hepatitis C receiving combination antiviral therapy with peginterferon and ribavirin , 2008, Journal of viral hepatitis.

[5]  C. Trépo,et al.  Prediction of Sustained Virological Response by Ribavirin Plasma Concentration at Week 4 of Therapy in Hepatitis C virus Genotype 1 Patients , 2008, Antiviral therapy.

[6]  P. Marquet,et al.  Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C , 2008, Hepatology.

[7]  V. Soriano,et al.  Measurement of Ribavirin Plasma Concentrations by High-performance Liquid Chromatography Using a Novel Solid-phase Extraction Method in Patients Treated for Chronic Hepatitis C , 2007, Therapeutic drug monitoring.

[8]  S. Sauleda,et al.  Early Monitoring of Ribavirin Serum Concentration is not Useful to Optimize Hepatitis C Virus treatment in HIV-Coinfected Patients , 2007, Antiviral therapy.

[9]  M. Cam,et al.  Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response , 2007, Hepatology.

[10]  R. van Leusen,et al.  Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  F. S. Rojas,et al.  Ribavirin: analytical determinations since the origin until today. , 2007, Journal of pharmaceutical and biomedical analysis.

[12]  A. Perelson,et al.  Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. , 2007, Journal of hepatology.

[13]  E. Snoeck,et al.  Pharmacokinetics of ribavirin in patients with hepatitis C virus. , 2006, British journal of clinical pharmacology.

[14]  G. di Perri,et al.  Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients. , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[15]  Christine R. Xu,et al.  Sensitive and specific LC-MS/MS method for the simultaneous measurements of viramidine and ribavirin in human plasma. , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[16]  R. Stauber,et al.  Ribavirin Levels and Haemoglobin Decline in Early Virological Responders and Non-Responders to Hepatitis C Virus Combination Therapy , 2006, Pharmacology.

[17]  J. Hoofnagle,et al.  Mechanism of action of interferon and ribavirin in treatment of hepatitis C , 2005, Nature.

[18]  V. Soriano,et al.  Early Monitoring of Ribavirin Plasma Concentrations May Predict Anemia and Early Virologic Response in HIV/Hepatitis C Virus-Coinfected Patients , 2005, Journal of acquired immune deficiency syndromes.

[19]  Yoshiyuki Suzuki,et al.  Significance of Serum Ribavirin Concentration in Combination Therapy of Interferon and Ribavirin for Chronic Hepatitis C , 2005, Intervirology.

[20]  A. Bruchfeld,et al.  High‐dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C , 2005, Hepatology.

[21]  N. Tanaka,et al.  Liquid Chromatography Assay for Routine Monitoring of Cellular Ribavirin Levels in Blood , 2004, Antimicrobial Agents and Chemotherapy.

[22]  N. Tanaka,et al.  Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[23]  P. Marcellin,et al.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.

[24]  N. Izumi,et al.  Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection. , 2003, British journal of clinical pharmacology.

[25]  G. Bessard,et al.  Ribavirin Quantification in Combination Treatment of Chronic Hepatitis C , 2003, Antimicrobial Agents and Chemotherapy.

[26]  A. Bruchfeld,et al.  Dosage of Ribavirin in Patients With Hepatitis C Should Be Based on Renal Function: A Population Pharmacokinetic Analysis , 2002, Therapeutic drug monitoring.

[27]  G. Hajian,et al.  Ribavirin dosing in chronic hepatitis C: Application of population pharmacokinetic‐pharmacodynamic models , 2002, Clinical pharmacology and therapeutics.

[28]  William M. Lee,et al.  Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. , 2002, Gastroenterology.

[29]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[30]  G. Hajian,et al.  Population Pharmacokinetic and Pharmacodynamic Analysis of Ribavirin in Patients With Chronic Hepatitis C , 2000, Therapeutic drug monitoring.

[31]  P. Glue,et al.  The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease. , 2000, British journal of clinical pharmacology.

[32]  F. Aweeka,et al.  High-Performance Liquid Chromatographic Determination of Ribavirin in Whole Blood To Assess Disposition in Erythrocytes , 1999, Antimicrobial Agents and Chemotherapy.

[33]  J. Patterson,et al.  Molecular mechanisms of action of ribavirin. , 1990, Reviews of infectious diseases.

[34]  M. Kagnoff,et al.  Sensitive radioimmunoassay for the broad-spectrum antiviral agent ribavirin , 1983, Antimicrobial Agents and Chemotherapy.

[35]  P. Glue,et al.  The clinical pharmacology of ribavirin. , 1999, Seminars in liver disease.